The investigation and treatment of secondary anaemia

Blood Reviews

Volumn 26, Issue 2, 2012, Pages 65-71

  Davis, Sarah L ^a   Littlewood, T J ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anaemia; Chronic disease; Erythropoiesis stimulating agents; Hepcidin; Intravenous iron

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; DEXTRIFERRON; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANAPHYLAXIS; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BLOOD ANALYSIS; BLOOD TRANSFUSION; CLINICAL EXAMINATION; DISEASE ASSOCIATION; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE DISTRIBUTION WIDTH; ERYTHROCYTE LIFESPAN; ERYTHROCYTE PARAMETERS; ERYTHROCYTE SEDIMENTATION RATE; ERYTHROPOIESIS; HOSPITAL PATIENT; HUMAN; INFECTION; IRON DEFICIENCY; KIDNEY DISEASE; LABORATORY TEST; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MEDICAL HISTORY; MEDICAL SPECIALIST; PATHOGENESIS; PATIENT CARE; PATIENT REFERRAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETICULOCYTE HEMOGLOBIN CONTENT; THROMBOEMBOLISM;

ANEMIA; CHRONIC DISEASE; HUMANS;

EID: 84856529685     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2011.10.003     Document Type: Article

References (55)

1. Weiss G., Goodnough L.T. Anaemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
2. Nissenson M.D., Goodnough L.T., Dubois R.W. Anemia: not just an innocent bystander?. Arch Intern Med 2003, 163:1400-1404.
3. Caro J.J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001, 91:2214-2221.
4. Krause A., Nietz S., Magert H.J., Schultz A., Forssmann W.G., Schultz-Knappe P., et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000, 480:147-150.
5. Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001, 276:7806-7810.
6. Nemeth E., Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009, 122:78-86.
7. Brasse-Lagnel C., Karim Z., Letteron P., Bekri S., Bado A., Beaumont C. Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. Gastroenterol 2011, 140:1261-1271.
8. Goodnough L.T., Nemeth E., Ganz T. Detection, evaluation and management of iron-restricted erythropoiesis. Blood 2010, 116:4754-4761.
9. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276.
10. Lee P., Peng H., Gelbart T., Wang L., Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 2005, 102:1906-1910.
11. Maes K., Nemeth E., Roodman G.D., Huston A., Esteve F., Freytes C., et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 2010, 116:3635-3644.
12. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998, 18:555-559.
13. Faquin W.C., Schneider T.J., Goldberg M.A. Effect of inflammatory cytokines on hypoxia induced erythropoietin production. Blood 1992, 79:1987-1994.
14. Cavill I., Auerbach M., Bailie G.R., Barrett-Lee P., Beguin Y., Kaltwasser P., et al. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin 2006, 22:731-738.
15. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterologica 2007, 132:2169-2180.
16. Marsh W.L., Bishop J.W., Darcy T.P. Evaluation of red cell distribution width (RDW). Hematol Pathol 1987, 1:117-123.
17. Cullis J. Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol 2011, 154:289-300.
18. Mast A.E., Blinder M.A., Gronowski A.M., Chumley C., Scott M.G. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998, 44:45-51.
19. Theurl I., Aigner E., Theurl M., Nairz M., Seifert M., Schroll A., et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009, 113:5277-5286.
20. Murphy A.T., Witcher D.R., Luan P., Wroblewski V.J. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 2007, 110:1048-1054.
21. Ganz T., Olbina G., Girelli D., Nemeth E., Westerman M. Immunoassay for human hepcidin. Blood 2008, 112:4292-4297.
22. Belperio P.S., Rhew D.C. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004, 116(S):27-43.
23. Vogelzang N.J., Breitbart W., Cella D., Curt G.A., Groopman J.E., Horning S.J., et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997, 34:4-12.
24. Littlewood T.J., Bajetta E., Nortier J.W.R., Vercammen E., Rapoport B. Effects of epoetin alfa on hematological parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19:2865-2874.
25. Clifford R., Littlewood T. Increased efficacy of anaemia treatment in cancer. Eur Haematol 2010, 4:8-10.
26. Bohlius J., Langensiepen S., Schwarzer G., Seidenfeld J., Piper M., Bennet C., et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2004, CD003407.
27. Seidenfeld J., Piper M., Aronson N. Systematic review of controlled trials on erythropoietin to support evidence-based guidelines. Oncology 2002, 16:171-188.
28. Littlewood T. Epoetin alfa (Eprex) and quality of life. Curr Med Res Opin 2005, 21(S2):S1-S2.
29. Wilson J., Yao G.L., Raftery J., Bohlius J., Brunskill S., Sandercock J., et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbopoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007, 11:1-202.
30. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Benentt C.L., Cella D., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002, 20:4083-4107.
31. Rizzo J.D., Brouwers M., Hurley P., Seidenfeld J., Arcasoy M.O., Spivak J.L., et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbopoetin in adult patients with cancer. J Clin Oncol 2010, 28:4996-5010.
32. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia. Natl Inst Health Clin Excell 2008.
33. Glapsy J., Crawford J., Vanstenkiste J., Henry D., Rao S., Bowers P., et al. Erythropoieses-stimulating agents in oncology: a study level meta-analysis of survival and other safety outcomes. Br J Cancer 2010, 102:301-315.
34. Winearls G.C., Oliver D.O., Pippard M.J., Reid C., Downing M.R., Cotes P.M. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 1986, 2:1175-1178.
35. Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Eng J Med 1987, 316:73-78.
36. Clinical Practice Guidelines for anemia of chronic kidney disease: update 2001. Am J Kidney Dis 2001, 37(S1):S182-S238.
37. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
38. Pfeffer M.A., Burdmann E.A., Chen C.Y., Cooper M.E., de Zeeuw D., Eckardt K.U., et al. A trial of darbepoietin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032.
39. Anaemia management in people with chronic kidney disease. Natl Inst Health Clin Excel 2011.
40. Ngo K., Kotecha D., Walters J.A.E., Manzano L., Palazzuoli A., van Veldhuisen D.J., et al. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010, CD007613.
41. Silverberg D.S., Iaina A., Peer G., et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996, 27(2):234-238.
42. Hedenus M., Birgegård G., Näsman P., Ahlberg L., Karlsson T., Lauri B., et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007, 21:627-632.
43. Auerbach M., Ballard H., Trout J.R., Mcilwain M., Ackerman A., Bahrain H., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multi-center, open-label, randomized trial. J Clin Oncol 2004, 22:1301-1307.
44. Bastit L., Vandebroek A., Altintas S., Gaede B., Pintér T., Suto T.S., et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008, 26:1611-1618.
45. Pedrazzoli P., Farris A., Del Prete S., Del Gaizo F., Ferrari D., Bianchessi C., et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoietin alpha. J Clin Oncol 2008, 26:1619-1625.
46. Henry D.H., Dahl N.V., Auerbach M., Tchekmedyian S., Laufman L.R. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007, 12:231-242.
47. Auerbach M., Silberstein P.T., Webb R.T., Averyanova S., Ciuleanu T.E., Shao J., et al. Darbepoetin alfa 300 or 500 γg every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anaemia. Am J Hematol 2010, 85:655-663.
48. Steensma D.P., Sloan J.L., Dakhil S.R., Dalton R., Kahanic S.P., Prager D.J., et al. Phase I.I.I. randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-induced anaemia. J Clin Oncol 2011, 29:97-105.
49. Anker S.D., Colet J.C., Filippatos G., Willenheimer R., Dickstein K., Drexler H., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Eng J Med 2009, 361:2436-2448.
50. Kim Y.T., Kim S.W., Yoon B.S., Cho H.J., Nahm E.J., Kim S.H., et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007, 105:199-204.
51. Dangsuwan P., Manchana T. Blood transfusion reduction with intravenous iron in gynaecologic patients receiving chemotherapy. Gynecol Oncol 2010, 116:522-525.
52. Auerbach M., Henry D. Parenteral iron therapy-taking the rust off. Haematology 2010, 338-347. Dece 2010.
53. Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Haematol 2010, 750643. Epub 2009 Dec 24.
54. Yu P.B., Hong C.C., Sachidanandan C., Babitt J.L., Deng D.Y., Hoyng S.A., et al. Nat Chem Biol 2008, 4:33-41.
55. Song S.N., Tomosugi N., Kawabata H., Ishikawa T., Nishikawa T., Yoshizaki K. Down-regulation of hepcidin resulting from long term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anaemia of inflammation in multicentric Castleman disease. Blood 2010, 116:3627-3634.